Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Top Cited Papers
- 30 July 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 376 (9737), 245-251
- https://doi.org/10.1016/s0140-6736(10)60893-8
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian CarcinomaCancer Research, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences of the United States of America, 2008
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesBMC Cancer, 2008
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- The PARP superfamilyBioEssays, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000